As the first research unit and standard drafting unit of Honghua Injection, Huawei Pharmaceutical has been committed to the research and development of Honghua series products for a long time. At present, it is the largest single variety enterprise of safflower injection in China, and also the largest R&D and production base of safflower in China. In view of the research and development achievements of safflower series products, Shanxi Economic and Trade Commission and other four departments awarded our company the title of "Shanxi Enterprise Technology Center", and Huawei Pharmaceuticals was also elected as "the first chairman unit of Shanxi Safflower Industry Alliance" by Shanxi Economic and Trade Commission and Medical Office.
In 1993, our company's safflower injection was awarded as "the best medicine product in China" and "national new product". In 2006, the preparation method of safflower injection was awarded the invention patent certificate of China National Intellectual Property Administration, and in 2007, the National Development and Reform Commission approved it as a national "high quality and high price Chinese patent medicine product". At present, it is the only safflower injection product in Shanxi Province that has won this honor.
On June 5438+ 10, 2009, entrusted by the National Pharmacopoeia Committee, Shanxi Institute for Drug Control organized 16 safflower injection production enterprises to hold the "Coordination Meeting on Improving the Quality Standard of Honghua Injection", and appointed Huawei Pharmaceutical as the lead unit to carry out the improvement of the national standard of Honghua Injection based on our company's production technology.